About US
Contact us
-
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed firstAndrew Obenshain officially took over as bluebird bio’s CEO when the company split into two back in November. But there’s one item from his prior desk that's still on his mind: the removal of Zyntegl2022/1/12
-
COVID-19 tracker: GSK, Vir to supply more antibody doses to US; BioNTech, InstaDeep develop variant early-warning systemWith the omicron variant surging, the U.S. has agreed to purchase additional doses of GlaxoSmithKline and Vir’s antibody treatment, which has been shown to retain its effectiveness against the new2022/1/10
-
JPM 2022: Pfizer CEO eyes 50% boost to Paxlovid production—and capacity expansions, tooDeveloping a COVID-19 vaccine at breakneck speed was a monumental achievement for Pfizer and BioNTech. The accompanying manufacturing effort is just as onerous. Similarly, as rapidly as2022/1/10
-
Pfizer carries pandemic momentum into 2022, scoring another huge Paxlovid deal with the USWith two COVID-fighting antiviral pills now on tap, the U.S. government is calling for a second helping of Pfizer’s treatment. The U.S. has doubled its order for Pfizer’s COVID-19 antivir2022/1/6
-
Merck, Pfizer, Lilly and J&J restored funding to legislators who stoked Jan. 6 Capitol attack, watchdog saysThe riot at the U.S. Capitol building last January compelled many American companies—including some pharma giants—to denounce the unrest and the legislators who helped foment it. Some companies mad2022/1/6
-
WuXi STA Passes the First U.S. FDA Drug Product Pre-Approval Inspection at its Shanghai Waigaoqiao siteSHANGHAI, CHINA, January 4, 2022 – WuXi STA – a subsidiary of WuXi AppTec, announced that its Waigaoqiao site in Shanghai, China, successfully passed the first drug product pre-approval inspection (2022/1/4
-
2022 forecast: Biopharma M&A lags in 2021. Will drugmakers still look for bolt-on deals or large transactions?In contrast to the bustling dealmaking by medtech and life sciences service businesses, merger and acquisition activity by drugmakers went largely quiet in 2021. But after all the slim-downs, biophar2021/12/30
-
Particulate problem prompts hold on 10 Gilead studies of HIV hopeful lenacapavirA second major HIV prospect has been put on hold, this time from Gilead Sciences. But unlike the recent halt on Merck's drug islatravir, which was related to a drop in trial patients' immune cell cou2021/12/30
-
Pfizer's megablockbuster-to-be COVID pill Paxlovid scores FDA nodIn the years-long battle against COVID-19, has a new age dawned with the emergence of antiviral pills to fight infection? On Wednesday, the FDAsanctionedPfizer’s Paxlovid for emergency use. The drug2021/12/28
-
Novartis aims to avoid pitfalls of earlier PCSK9 launches with its new blockbuster hopeful LeqvioAfter a surprising FDA rejection and a change in manufacturing facility, Novartis has won FDA backing for its blockbuster hopeful Leqvio. With an additional year of preparation and a unique marketing2021/12/28